[关键词]
[摘要]
目的 探究中医药治疗颈动脉粥样硬化(CAS)临床研究的现状、热点及趋势。方法 检索中国知网(CNKI)、万方(Wanfang)、维普(VIP)、Web of Science核心合集数据库相关文献,采用Python 3.9.6清洗数据,运用CiteSpace和VOSviewer对作者、机构、关键词等进行可视化分析。结果 纳入910篇中文文献、5篇英文文献;发文最多的作者为王长垠和殷春萍、机构为河北省邯郸市中医院,机构间合作关系较独立,地域性较明显;研究热点集中于:痰瘀互结、血脂异常、炎症因子、血管内皮功能、神经功能缺损、半夏白术天麻汤、冠心病等;从“痰瘀互结”论治CAS将持续成为该领域的研究热点。结论 中医药治疗CAS临床研究需观察疗效与揭示机制紧密结合,应探索治疗CAS的中药用药规律,未来着重从“痰瘀互结”论治CAS,应系统深入探究“痰瘀互结”病机原理、化痰祛瘀方药治疗CAS的药效及机制。
[Key word]
[Abstract]
Objective To explore the current situation, hot spots and trends of clinical research on the treatment of carotid atherosclerosis (CAS) with traditional Chinese medicine. Methods Search CNKI, Wanfang, VIP, Web of Science core collection database related literature, using Python 3.9.6 cleaning data, using CiteSpace and VOSviewer for visual analysis of authors, institutions, keywords, etc. Results 910 Chinese literatures and 5 English literatures were included. The most published authors were Wang Changyin and Yin Chunping, and the institution was Handan Hospital of Traditional Chinese Medicine, Hebei Province. The cooperation between institutions was independent and regional. Research focus on: phlegm stasis interjunction, dyslipidemia, inflammatory factors, vascular endothelial function, nerve function defect, Banxia Baizhu Tianma decoction, coronary heart disease and so on; The treatment of CAS from "interjunction of phlegm and blood stasis" will continue to become a research hotspot in this field. Conclusion The clinical research of traditional Chinese medicine in the treatment of CAS should be closely combined with the observation of curative effect and the revelation of mechanism, and the law of traditional Chinese medicine in the treatment of CAS should be explored. In the future, the treatment of CAS should focus on the treatment of " phlegm and blood stasis ", and the pathogenesis principle of " phlegm and blood stasis ", the efficacy and mechanism of resolving phlegm and removing blood stasis in the treatment of CAS should be systematically and deeply explored.
[中图分类号]
[基金项目]
国家中医药管理局中医药创新团队及人才支持计划项目(ZYYCXTD-D-202005)